Gene Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Gene Therapy Market
The global gene therapy market size was valued at USD 3.61 billion in 2019 and is projected to grow to USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period of 2020-2027.
The COVID-19 pandemic affected the gene therapy market by slowing down clinical trials, stopping the studies, and affecting the delivery logistics of vital product components. But at the same time, it highlighted the cost of innovating therapeutic health products, hence enhancing investors’ contribution and accelerating the time for approval of the industry, hindering the gene therapy market growth.
The gene therapy marketplace is pushed via improvements in biotechnology, the growing occurrence of genetic issues, and increasing investment in studies and development. The developing reputation of personalized medication and favorable regulatory frameworks guide the increase in the marketplace.
Advanced gene-modifying technology is revolutionizing the sphere of gene remedy. CRISPR-Cas9 is an effective device that allows precise and efficient adjustments to the human genome, opening up new possibilities for treating genetic sicknesses and expanding the gene therapy market share globally. Base enhancing techniques provide even more precision, taking into consideration focused adjustments to man or woman DNA bases. These improvements pave the way for the improvement of transformative cures for various genetic issues.
Comprehensive Analysis of Gene Therapy Market
The gene therapy market is segmented via application, vector kind, and distribution channels. In utility, the neurology phase held the most significant percentage due to the high cost and adoption of therapies for conditions like spinal muscular atrophy. Simultaneously, the oncology segment is poised for a substantial increase pushed via robust research and pipeline trends for cancer remedies. By vector kind, viral vectors ruled, with Adeno-Associated Virus (AAV) being widely used for its safety and efficacy. In contrast, non-viral vectors are projected to develop at a slower pace. For distribution channels, hospitals held the highest share due to better accessibility and availability of superior treatment methods, with clinics also displaying an increase as more standalone centers provide specialized treatment options.
The North America region led the gene therapy market by benefitting a size of USD 2.16 billion in 2019 due to favorable guidelines and reimbursement guidelines; the marketplace growth in the US Is anticipated to be supported.
The leading players in the gene therapy market play a pivotal role in shaping its growth trajectory and establishing industry benchmarks. These key companies, including Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc., Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, and other prominent players, contribute to a highly competitive landscape. Their efforts drive innovation, advance therapeutic solutions, and foster market expansion globally.
In June 2021, Biogen Inc. Stated favorable outcomes from its Phase 3 STAR study comparing timrepigene emparvovec (BIIB111/AAV2-REP1), an experimental gene therapy designed to deal with choroideremia.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD billion)
SegmentationBy Application
Oncology
Neurology
Others
By Vector Type
Viral
Non-viral
By Distribution Channel
Hospitals
Clinics
Others
By Geography
U.S
Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
Asia-Pacific (Japan, China, and Rest of Asia- Pacific)
Rest of World
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Overview of Regulatory Scenario
- 4.2. Key Product Launches/Recalls
- 4.3. Pipeline Analysis
- 4.4. Scientific Advancements in Gene Therapy
- 4.5. Key Industry developments - Mergers, Acquisitions and Partnerships
- 4.6. Patent Analysis
- 4.7. COVID-19 Impact on Gene Therapy Market
- 5. Global Gene Therapy Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Application
- 5.2.1. Oncology
- 5.2.2. Neurology
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By Vector Type
- 5.3.1. Viral
- 5.3.2. Non-viral
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospitals
- 5.4.2. Clinics
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast – By Country
- 5.5.1. U.S
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Rest of World
- 6. U.S Gene Therapy Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Application
- 6.2.1. Oncology
- 6.2.2. Neurology
- 6.2.3. Others
- 6.3. Market Analysis – By Vector Type
- 6.3.1. Viral
- 6.3.2. Non-viral
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospitals
- 6.4.2. Clinics
- 6.4.3. Others
- 7. Europe Gene Therapy Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Application
- 7.2.1. Oncology
- 7.2.2. Neurology
- 7.2.3. Others
- 7.3. Market Analysis – By Vector Type
- 7.3.1. Viral
- 7.3.2. Non-viral
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospitals
- 7.4.2. Clinics
- 7.4.3. Others
- 7.5. Market Analysis – By Country
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Rest of Europe
- 8. Asia Pacific Gene Therapy Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Application
- 8.2.1. Oncology
- 8.2.2. Neurology
- 8.2.3. Others
- 8.3. Market Analysis – By Vector Type
- 8.3.1. Viral
- 8.3.2. Non-viral
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospitals
- 8.4.2. Clinics
- 8.4.3. Others
- 8.5. Market Analysis – By Country
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. Rest of Asia Pacific
- 9. Rest of World Gene Therapy Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Application
- 9.2.1. Oncology
- 9.2.2. Neurology
- 9.2.3. Others
- 9.3. Market Analysis – By Vector Type
- 9.3.1. Viral
- 9.3.2. Non-viral
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospitals
- 9.4.2. Clinics
- 9.4.3. Others
- 9.5. Market Analysis – By Country
- 10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2019)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis – Major Players
- 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 10.5.1. Novartis AG
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Spark Therapeutics, Inc.
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. Biogen
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. Gilead Sciences, Inc
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. Amgen, Inc.
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. Jazz Pharmaceuticals, Inc.
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability)
- 10.5.7. Sarepta Therapeutics
- 10.5.7.1. Overview,
- 10.5.7.2. Products & services,
- 10.5.7.3. SWOT analysis,
- 10.5.7.4. Recent developments,
- 10.5.7.5. strategies,
- 10.5.7.6. financials (based on availability)
- 10.5.8. GlaxoSmithKline plc
- 10.5.8.1. Overview,
- 10.5.8.2. Products & services,
- 10.5.8.3. SWOT analysis,
- 10.5.8.4. Recent developments,
- 10.5.8.5. strategies,
- 10.5.8.6. financials (based on availability)
- 10.5.9. Other Prominent Players
- 10.5.9.1. Overview,
- 10.5.9.2. Products & services,
- 10.5.9.3. SWOT analysis,
- 10.5.9.4. Recent developments,
- 10.5.9.5. strategies,
- 10.5.9.6. financials (based on availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook